MEDFORD, Mass.--ArQule here and Genome Therapeutics of Waltham, Mass., announced they will collaborate to discover novel drugs to combat bacterial and fungal diseases. ArQule will screen its proprietary chemical libraries against Genome Therapeutics' bacterial and fungal disease targets to identify and optimize small molecule antiinfectives.
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
Not ready for premium?
Register for Free ContentYou can still register for access to our free content.